Plain-English translation of NCT06621121 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This real-world study is comparing two medications that doctors use to treat ischemic stroke (stroke caused by a blood clot). One medication is called tenecteplase, and the other is alteplase. Both are designed to dissolve the clot quickly and restore blood flow to the brain during the critical first few hours after a stroke.
Doctors need to know which of these two clot-busting medications works better, is safer, and is more cost-effective for different patients. This information will help them choose the best treatment for each person having a stroke.
You likely qualify if…
You likely don't qualify if…
You would receive one of the two medications as an emergency treatment in the hospital. Your medical team would check on you closely with assessments at 24, 36, and 72 hours after treatment, then again at day 7 (or when you leave the hospital) and at day 90. These check-ins measure how well you're recovering and whether you've experienced any side effects.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
China
Enrollment target
~6,000 participants
Started
October 2024
Primary completion
October 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in October 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Shoufeng Liu, MD
Tianjin Huanhu Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.